OrbusNeich Medical Group Holdings Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
David Chien
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 79.8% |
| CEO tenure | 8.2yrs |
| CEO ownership | n/a |
| Management average tenure | 6yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
OrbusNeich Medical Group Holdings (HKG:6929) Seems To Use Debt Rather Sparingly
Dec 04
Some Confidence Is Lacking In OrbusNeich Medical Group Holdings Limited (HKG:6929) As Shares Slide 28%
Jul 19OrbusNeich Medical Group Holdings Limited (HKG:6929) Shares Could Be 39% Below Their Intrinsic Value Estimate
Jul 03Is OrbusNeich Medical Group Holdings (HKG:6929) A Risky Investment?
May 28Optimistic Investors Push OrbusNeich Medical Group Holdings Limited (HKG:6929) Shares Up 27% But Growth Is Lacking
May 06OrbusNeich Medical Group Holdings' (HKG:6929) Earnings Are Weaker Than They Seem
Apr 25Some Confidence Is Lacking In OrbusNeich Medical Group Holdings Limited (HKG:6929) As Shares Slide 26%
Mar 13Returns At OrbusNeich Medical Group Holdings (HKG:6929) Appear To Be Weighed Down
Feb 04A Look At The Intrinsic Value Of OrbusNeich Medical Group Holdings Limited (HKG:6929)
Oct 20Some OrbusNeich Medical Group Holdings Limited (HKG:6929) Shareholders Look For Exit As Shares Take 28% Pounding
Jun 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$39m |
| Mar 31 2024 | n/a | n/a | US$42m |
| Dec 31 2023 | US$1m | US$808k | US$45m |
| Sep 30 2023 | n/a | n/a | US$40m |
| Jun 30 2023 | n/a | n/a | US$36m |
| Mar 31 2023 | n/a | n/a | US$27m |
| Dec 31 2022 | US$1m | US$769k | US$18m |
| Sep 30 2022 | n/a | n/a | US$9m |
| Jun 30 2022 | n/a | n/a | US$272k |
| Mar 31 2022 | n/a | n/a | -US$2m |
| Dec 31 2021 | US$355k | US$326k | -US$4m |
| Dec 31 2020 | US$335k | US$320k | US$7m |
| Dec 31 2019 | US$336k | US$308k | US$7m |
Compensation vs Market: David's total compensation ($USD1.01M) is above average for companies of similar size in the Hong Kong market ($USD392.88K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Chien (59 yo)
8.2yrs
Tenure
US$1,012,000
Compensation
Mr. David Chien serves as Chairman of the Board of OrbusNeich Medical Group Holdings Limited and serves as its Chief Executive Officer since November 11, 2016. Mr. Chen has served as Director of OrbusNeic...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 8.2yrs | US$1.01m | no data | |
| CFO, Company Secretary & Executive Director | 7yrs | US$569.00k | no data | |
| COO & Executive Director | 4.3yrs | US$702.00k | no data | |
| Chief Commercial Officer | 5yrs | no data | no data |
6.0yrs
Average Tenure
51yo
Average Age
Experienced Management: 6929's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 3.5yrs | US$1.01m | no data | |
| CFO, Company Secretary & Executive Director | 3.5yrs | US$569.00k | no data | |
| COO & Executive Director | 3.5yrs | US$702.00k | no data | |
| Independent Non-Executive Director | 3.3yrs | US$31.00k | no data | |
| Non-Executive Director | 3.3yrs | no data | no data | |
| Independent Non-Executive Director | 3.3yrs | US$31.00k | no data | |
| Independent Non-Executive Director | 3.3yrs | US$31.00k | no data | |
| Non-Executive Director | 3.5yrs | US$279.94k | 0.037% HK$ 1.1m | |
| Non-Executive Director | 1.7yrs | US$19.00k | no data |
3.3yrs
Average Tenure
49yo
Average Age
Experienced Board: 6929's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 01:03 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OrbusNeich Medical Group Holdings Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |
| null null | China International Capital Corporation Limited |